Elisa Redl

Elisa Redl

Auto-generated profile, based on publicly available information

Elisa Redl

European Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LSLena Schreiberhuber
Lena Schreiberhuber
JBJames E. Barrett
James E. Barrett
JWJiangrong Wang
Jiangrong Wang
ERElisa Redl
Elisa Redl
CHChiara Herzog
Chiara Herzog
MWMartin Widschwendter
Martin Widschwendter
Cervical cancer (CC) screening in women comprises human papillomavirus (HPV) testing followed by cytology triage of positive cases. Drawbacks, including cytology’s low reproducibility and requirement for short screening intervals, raise the need for alternative triage methods. Here we used an innovative triage technique, the WID-qCIN test, to assess the DNA methylation of human genes DPP6, RALYL and GSX1 in a real-life cohort of 28,017 women aged ≥30 years who attended CC screening in Stockholm between January and March 2017. In the analysis of all 2,377 HPV-positive samples, a combination of WID-qCIN (with a predefined threshold) and HPV16 and/or HPV18 (HPV16/18) detected 93.4% of cervical intraepithelial neoplasia grade 3 and 100% of invasive CCs. The WID-qCIN/HPV16/18 combination predicted 69.4% of incident cervical intraepithelial neoplasia grade 2 or worse compared with 18.2% predicted by cytology. Cytology or WID-qCIN/HPV16/18 triage would require 4.1 and 2.4 colposcopy referrals to detect one cervical intraepithelial neoplasia grade 2 or worse, respectively, during the 6 year period. These findings support the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women.

2 April 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
CHChiara M. S. Herzog
Chiara M. S. Herzog
ERElisa Redl
Elisa Redl
JBJames Barrett
James Barrett
SASepideh Aminzadeh-Gohari
Sepideh Aminzadeh-Gohari
DWDaniela Weber
Daniela Weber
MWMartin Widschwendter
Martin Widschwendter
Background: Aging is a key risk factor for many diseases, including cancer, and a better understanding of its underlying molecular mechanisms may help to prevent, delay, or treat age-related pathologies. Epigenetic alterations such as DNA methylation (DNAme) changes are a hallmark of aging and form the basis of so-called epigenetic clocks, yet their functional relevance and directionality in different organs during disease development is often unclear. Methods: Here, we link cell-specific age-related DNAme changes with three key hallmarks of aging and cancer (senescence, promoter methylation in genes associated with stem cell fate, and dysregulated proliferation) to comprehensively dissect their association with current and future cancer development, carcinogen exposure or preventive measures, and mortality using data in different organs from over 12,510 human and 105 mouse samples, benchmarking against existing epigenetic clocks. Results: Our findings offer insights into the association of functionally enriched groups of age-related DNAme changes with cancer, identify sites perturbed earliest during carcinogenesis, as well as those distinct between cancer and reprogramming that could inform strategies to prevent teratoma formation upon in vivo reprogramming. Surprisingly, both mouse and human data reveal accelerated aging in breast cancer tissue but decelerated epigenetic aging in some non-cancer surrogate samples from breast cancer patients, in particular cervical samples. Conclusions: This work provides evidence for discordant systemic tissue aging in breast cancer.

13 May 2024 in International Journal of Cancer
Verified
Journal Article
Open access
OIOjone Illah
Ojone Illah
MSMalcolm Scott
Malcolm Scott
ERElisa Redl
Elisa Redl
JBJames E. Barrett
James E. Barrett
LSLena Schreiberhuber
Lena Schreiberhuber
MWMartin Widschwendter
Martin Widschwendter
Endometrial cancer (EC) is the most prevalent gynaecological cancer in high‐income countries and its incidence is continuing to rise sharply. Simple and objective tools to reliably detect women with EC are urgently needed. We recently developed and validated the DNA methylation (DNAme)‐based women's cancer risk identification—quantitative polymerase chain reaction test for endometrial cancer (WID‐qEC) test that could address this need. Here, we demonstrate that the stability of the WID‐qEC test remains consistent regardless of: (i) the cervicovaginal collection device and sample media used (Cervex brush and PreservCyt or FLOQSwab and eNAT), (ii) the collector of the specimen (gynaecologist‐ or patient‐based), and (iii) the precise sampling site (cervical, cervicovaginal and vaginal). Furthermore, we demonstrate sample stability in eNAT medium for 7 days at room temperature, greatly facilitating the implementation of the test into diagnostic laboratory workflows. When applying FLOQSwabs (Copan) in combination with the eNAT (Copan) sample collection media, the sensitivity and specificity of the WID‐qEC test to detect uterine (i.e., endometrial and cervical) cancers in gynaecologist‐taken samples was 92.9% (95% confidence interval [CI] = 75.0%–98.8%) and 98.6% (95% CI = 91.7%–99.9%), respectively, whilst the sensitivity and specificity in patient collected self‐samples was 75.0% (95% CI = 47.4%–91.7%) and 100.0% (95% CI = 93.9%–100.0%), respectively. Taken together these data confirm the robustness and clinical potential of the WID‐qEC test.

10 December 2024 in International Journal of Cancer
Verified
Journal Article
Open access
SKSebastian Ken‐Amoah
Sebastian Ken‐Amoah
ERElisa Redl
Elisa Redl
BDBright K. S. Domson
Bright K. S. Domson
JBJames E. Barrett
James E. Barrett
LSLena Schreiberhuber
Lena Schreiberhuber
MWMartin Widschwendter
Martin Widschwendter
The burden of uterine cancer is growing and, in the US and UK, mortality rates are poorest among black women. Early detection of these cancers is critical and poor performance of ultrasound in black women may contribute to adverse outcomes. Limited data on this topic are available from Africa. We assessed whether a simple DNA methylation test, the WID‐qEC, enables detection of all epithelial uterine (endometrial and cervical) cancers in women presenting with abnormal uterine bleeding (AUB) in Ghana. Among 118 women ≥40 years presenting with AUB, 106 consented to the study and a cervicovaginal sample was obtained for WID‐qEC testing. Subsequent to ultrasound assessment 102 women had a cervical or endometrial biopsy. Histopathology, ultrasound and WID‐qEC testing were analyzed and compared. Among the 102 volunteers, 8 and 15 were diagnosed with endometrial and cervical cancer (EC and CC), respectively. The receiver operating characteristic (ROC) area under the curve (AUC) was 0.56 (95% confidence interval [CI] 0.25–0.86) for sonographic endometrial thickness (ET) and 0.98 (95% CI 0.94–1.00) for the WID‐qEC test. Sensitivity and specificity of the prespecified ET ≥5 mm were 66.7% (95% CI 24.1–94.0) and 22.7 (95% CI 12.0–38.2) and for the prespecified WID‐qEC SUM‐PMR ≥ 0.3 were 100% (95% CI 56.1–100.0) and 76.1 (96%CI 60.9–86.9), respectively. In addition, 15 CCs were detected by the WID‐qEC test [sensitivity 100% (95% CI 74.7–100.0)]. The WID‐qEC test accurately detects both EC and CC in black women presenting with AUB.

2 April 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
JBJames E. Barrett
James E. Barrett
CHChiara Maria Herzog
Chiara Maria Herzog
SASepideh Aminzadeh-Gohari
Sepideh Aminzadeh-Gohari
ERElisa Redl
Elisa Redl
IPIsma Ishaq Parveen
Isma Ishaq Parveen
MWMartin Widschwendter
Martin Widschwendter
Background: In order to advance personalized primary cancer prevention, surrogate endpoint biomarkers in distant, easy to access tissues (i.e., field defect indicators) reflecting field cancerization in the organ at risk are essential. Methods: Here we utilized medroxyprogesterone acetate and 7,12-dimethylbenzanthracene to induce mammary gland cancers in mice. We assessed epigenetic signatures reflective of carcinogen exposure, cell-type composition, mitotic age, and methylation at progesterone receptor binding sites in both, the tissue at risk (normal mammary gland; field cancerization) and distant non-at-risk organs (cervix, oviduct, and blood; field defect indicators), in mice that did and did not develop mammary gland cancers. Results: We demonstrate that the anti-progestine mifepristone reduces the cancer risk by more than 50%. Importantly, the reduction in cancer risk is accompanied by a decline in both field cancerization and field defect indicators; specifically, epigenetic signatures in the cervix are predictive of mammary cancer formation but show tissue-specific directionality. Conclusions: These data encourage further exploration of epigenetic biomarkers in certain field defect-indicating tissues with a view to monitor the efficacy of cancer prevention strategies in humans.

1 September 2025 in bioRxiv
Verified
Preprint
Open access
CHChiara Ms Herzog
Chiara Ms Herzog
CVCharlotte Vavourakis
Charlotte Vavourakis
ERElisa Redl
Elisa Redl
MHMagdalena Hagen
Magdalena Hagen
GKGabriel Knoll
Gabriel Knoll
MWMartin Widschwendter
Martin Widschwendter
Summary: Extending human healthspan requires understanding how lifestyle interventions impact molecular systems across tissues and time. Here, we present the TirolGESUND Lifestyle Atlas (ClinicalTrials.gov: NCT05678426 ), a longitudinal, multi-modal resource profiling 156 healthy women (aged 30-60 years) undergoing 6-month intermittent fasting (n=114) or smoking cessation (n=42) interventions. Participants were sampled up to four times across seven tissues and fluids, generating >3,450 biospecimens with harmonised DNA methylation, metabolomics, microbiome, and immune profiling, alongside skin histology, barrier measurements, and rich clinical metadata. We demonstrate the utility of this dataset through: (i) multi-omics-wide association studies linking traits to molecular features; (ii) integrative factor modelling revealing coordinated cross-tissue signatures; (iii) epigenetic-biomarker cross-omic associations, and (iv) CpG-level variance decomposition mapping stable, individual-specific, tissue-restricted, and intervention-responsive methylation patterns. We further show that ageing-linked features are selectively malleable: highly compliant intermittent fasting participants exhibited attenuated or even age-opposing molecular trajectories within six months. The atlas enables unprecedented within-cohort comparisons across omic layers and tissues, supporting discovery of context-dependent biomarkers, cross-system coordination, and intervention responsiveness. Data are available via an interactive portal, with sensitive data under controlled access ( https://eutops.github.io/lifestyle-atlas/ ). This resource provides a foundation for exploring biomarker association and multi-tissue epigenetics, enabling hypothesis generation and benchmarking for systems biology and human healthspan research. Graphical Highlights: Multi-tissue multi-modal profiling of two clinically-relevant lifestyle interventions in 156 women aged 30-60 Intermittent fasting modifies ageing-linked molecular features in an age-opposing direction Cross-tissue epigenetic biomarker mapping links immunity, metabolism, and microbiome Tissue-specific epigenetic plasticity maps reveal candidate meQTLs, Data sharing and interactive portal enable broad reuse for hypothesis generation and exploration